Shares of Propanc Biopharma, Inc. (OTCMKTS:PPCB – Get Free Report) dropped 6.4% during mid-day trading on Friday . The company traded as low as $2.62 and last traded at $2.62. Approximately 3,663 shares changed hands during trading, an increase of 189% from the average daily volume of 1,266 shares. The stock had previously closed at $2.80.
Propanc Biopharma Stock Performance
The stock’s 50-day moving average price is $5.45 and its 200-day moving average price is $3.38.
About Propanc Biopharma
Propanc Biopharma, Inc, a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes.
Featured Stories
- Five stocks we like better than Propanc Biopharma
- How Investors Can Find the Best Cheap Dividend Stocks
- Constellation Powers Up With Reinforced AI Data Center Strategy
- What is a Death Cross in Stocks?
- Top Analyst-Rated Healthcare Stocks to Watch Now
- 5 Top Rated Dividend Stocks to Consider
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
